7/17
10:43 pm
trvi
Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market [Yahoo! Finance]
Neutral
Report
Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market [Yahoo! Finance]
6/20
01:01 am
trvi
Low
Report
6/17
07:30 am
trvi
Trevi Therapeutics Announces Upcoming June and July Event Schedule
Medium
Report
Trevi Therapeutics Announces Upcoming June and July Event Schedule
6/3
10:08 am
trvi
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. [Yahoo! Finance]
Low
Report
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. [Yahoo! Finance]
5/20
01:21 pm
trvi
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $23.00 price target on the stock.
Low
Report
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $23.00 price target on the stock.
5/9
05:18 am
trvi
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 [Yahoo! Finance]
Medium
Report
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 [Yahoo! Finance]
5/8
10:00 am
trvi
Trevi Therapeutics (TRVI) was given a new $30.00 price target by Stifel Nicolaus.
Low
Report
Trevi Therapeutics (TRVI) was given a new $30.00 price target by Stifel Nicolaus.
5/6
12:28 pm
trvi
Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030 [Yahoo! Finance]
Low
Report
Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030 [Yahoo! Finance]
5/6
09:00 am
trvi
Trevi Therapeutics (TRVI) had its "overweight" rating reaffirmed by Morgan Stanley.
Medium
Report
Trevi Therapeutics (TRVI) had its "overweight" rating reaffirmed by Morgan Stanley.
5/6
08:24 am
trvi
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by HC Wainwright. They now have a $21.00 price target on the stock.
Medium
Report
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by HC Wainwright. They now have a $21.00 price target on the stock.
5/6
08:00 am
trvi
Trevi Therapeutics (TRVI) had its price target lowered by Needham & Company LLC from $24.00 to $23.00. They now have a "buy" rating on the stock.
Low
Report
Trevi Therapeutics (TRVI) had its price target lowered by Needham & Company LLC from $24.00 to $23.00. They now have a "buy" rating on the stock.
5/6
12:23 am
trvi
Trevi Therapeutics Q1 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Trevi Therapeutics Q1 Earnings Call Highlights [Yahoo! Finance]
5/5
04:21 pm
trvi
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates [Yahoo! Finance]
Low
Report
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates [Yahoo! Finance]
5/5
04:05 pm
trvi
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Low
Report
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
4/30
04:05 pm
trvi
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
Low
Report
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
4/28
04:05 pm
trvi
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026
Low
Report
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026
4/23
04:12 pm
trvi
Trevi Therapeutics to Participate in Upcoming May Events [Yahoo! Finance]
Medium
Report
Trevi Therapeutics to Participate in Upcoming May Events [Yahoo! Finance]
4/23
04:05 pm
trvi
Trevi Therapeutics to Participate in Upcoming May Events
Low
Report
Trevi Therapeutics to Participate in Upcoming May Events
4/22
06:08 am
trvi
Trevi Therapeutics (TRVI) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Low
Report
Trevi Therapeutics (TRVI) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
4/20
04:05 pm
trvi
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
Medium
Report
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares